Randomized, placebo-controlled clinical trial on the efficacy of a mouthrinse containing 0.1% benzalkoniumchloride on the reduction of intraoral viral load and infectivity in SARS-CoV-2 positive subjects (COVID-19)

Not Applicable

Completed

• Conditions: U07.1; COVID-19, virus identified

• Registration Number: DRKS00024454
• Lead Sponsor: Poliklinik für Zahnerhaltung und ParodontologieUniversitätsklinikum Regensburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-02-06
• Study Start: 2021-02-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

positive SARS-CoV-2 detection within the last 72 h

Exclusion Criteria

- Indication for intubation or mechanical ventilation
- severe stomatitis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of intraoral SARS-CoV-2 viral load (detection of viral load immediately before rinsing with benzalkonium chloride and 15 min and 30 min after rinsing with benzalkonium chloride by RT-PCR compared to placebo control).<br><br> <br>

Secondary Outcome Measures

Name	Time	Method
Reduction of intraoral SARS-CoV-2 infectivity (virus culture immediately before rinsing with benzalkonium chloride and 15 min and 30 min after rinsing with benzalkonium chloride as compared to placebo control).